Clinical trials for patients with newly diagnosecd glioblastoma (WHO grade IV)

This is a list of clinical trials offered to patients with glioblastoma at the time of diagnosis. In some studies patients are stratified according to the activity of the DNA repair gene MGMT in the tumor tissue.

 

• Radiation therapy and concomittant low-dose indomethacin  and temozolomide plus adjuvant temozolomide (one week on/one week off) for newly diagnosed glioblastoma: a phase II study.

Status: active, not recruiting, 42 patients accrued.

Site Heidelberg: Principal investigator, results submitted for publication

 

• NOA-08: Temozolomide (one week on/one week off) versus radiation therapy of newly diagnosed anaplastic astrocytomas and glioblastomas in elderly patients: a randomised phase III-study. Status: active, recruiting, 238/340 patients accrued (January 2008)Site Heidelberg: Principal investigator, recruiting

 

• EORTC 26052/RTOG0525: Phase-III-study comparing dose-intensive adjuvant temozolomide with conventional temozolomide in patients with newly diagnosed glioblastoma.

Status: active, recruiting, 469/840 patients accrued (07/2007).

Site Heidelberg: Principal investigator Germany

 

• Enzastaurin and radiation therapy for patients with newly diagnosed glioblastoma without methylated MGMT pomotor: a phase I/II study
  

Status: active, recruiting

Site Heidelberg: Principal investigator

 

• Phase-III Studie of standard radiochemotherapy plus concomittant and adjuvant OSAG 101 (Theraloc®) versus standard radiochemotherapy in patients with newly diagnosed glioblastoma.

Status: not active, open for accrual first quarter of 2008

Site Heidelberg: Contact Dr. M. Halatsch, department of neurosurgery for further information